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Abstract
The increasing frequency, severity and antimicrobial resistance of Staphylococcus aureus infections has made the
development of immunotherapies against this pathogen more urgent than ever. Previous immunization attempts using
monovalent antigens resulted in at best partial levels of protection against S. aureus infection. We therefore reasoned that
synthesizing a bivalent conjugate vaccine composed of two widely expressed antigens of S. aureus would result in additive/
synergetic activities by antibodies to each vaccine component and/or in increased strain coverage. For this we used
reductive amination, to covalently link the S. aureus antigens clumping factor A (ClfA) and deacetylated poly-N-b-(1–6)-
acetyl-glucosamine (dPNAG). Mice immunized with 1, 5 or 10 mg of the dPNAG-ClfA conjugate responded in a dose-
dependent manner with IgG to dPNAG and ClfA, whereas mice immunized with a mixture of ClfA and dPNAG developed
significantly lower antibody titers to ClfA and no antibodies to PNAG. The dPNAG-ClfA vaccine was also highly
immunogenic in rabbits, rhesus monkeys and a goat. Moreover, affinity-purified, antibodies to ClfA from dPNAG-ClfA
immune serum blocked the binding of three S. aureus strains to immobilized fibrinogen. In an opsonophagocytic assay
(OPKA) goat antibodies to dPNAG-ClfA vaccine, in the presence of complement and polymorphonuclear cells, killed S.
aureus Newman and, to a lower extent, S. aureus Newman DclfA. A PNAG-negative isogenic mutant was not killed.
Moreover, PNAG antigen fully inhibited the killing of S. aureus Newman by antisera to dPNAG-ClfA vaccine. Finally, mice
passively vaccinated with goat antisera to dPNAG-ClfA or dPNAG-diphtheria toxoid conjugate had comparable levels of
reductions of bacteria in the blood 2 h after infection with three different S. aureus strains as compared to mice given
normal goat serum. In conclusion, ClfA is an immunogenic carrier protein that elicited anti-adhesive antibodies that fail to
augment the OPK and protective activities of antibodies to the PNAG cell surface polysaccharide.
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Introduction
Staphylococcus aureus is a leading etiology of hospital-acquired
infections worldwide. This versatile organism, including strains
with a troublesome pattern of antibiotic resistance as accentuated
by methicillin-resistant S. aureus (MRSA), cause a wide spectrum of
diseases that range from mild skin and soft tissue infections to more
severe invasive ones such as endocarditis, blood and lower
respiratory tract infections, septic arthritis, osteomyelitis or deep-
seated abscesses among others [1,2]. With the emergence of these
many difficult-to-treat strains the need to develop new antimicro-
bials and/or immunotherapeutic approaches to combat infections
is more urgent than ever.
S. aureus elaborates a large collection of virulence factors
including pore-forming toxins, superantigens, phagocytosis-eva-
sion molecules and inhibitors of host immune effectors, as well as
variably encoded and expressed microbial surface components
recognizing adhesive matrix molecules (MSCRAMMs). Among
these, a fair number have been tested individually as vaccine
targets in preclinical studies using either active or passive
immunization, including the capsular polysaccharides types 5
and 8 (CP5 and CP8), alpha-toxin (non-toxic derivative H35L),
Panton-Valentine leukocidin (PVL), enterotoxins B, A, C1,
nontoxic mutant toxic shock syndrome toxin 1 (TSST), lipotei-
choic acid (LTA), and other virulence factors carrying the LPXTG
motif needed for anchoring to the cell wall, such as fibronectin
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ing factor A (ClfA), and the iron surface determinant B protein
(IsdB) [3]. Some vaccine antigens including CP5 and CP8
conjugate vaccines, the IsdB antigen, human polyclonal antibodies
to ClfA and a humanized monoclonal antibody to LTA have
reached phase III human trials. Despite promising results obtained
in pre-clinical studies, all have failed to meet their defined
endpoints in preventing S. aureus infection [3]. As a result of these
disappointing outcomes with monovalent vaccine components, a
shift towards use of polyvalent vaccines has garnered significant
interest.
To asses if additive or synergistic protection could be
engendered in a multivalent vaccine, we evaluated a conjugate
vaccine composed of two highly conserved S. aureus surface
antigens, poly-N-b-(1–6)-acetyl-glucosamine (PNAG) and ClfA by
using the protection-inducing deacetylated glycoform of PNAG
(dPNAG) [4] conjugated to ClfA as a vaccine candidate against S.
aureus infections. Previous work carried out in our laboratory has
already demonstrated the ability of a vaccine composed of dPNAG
conjugated to the carrier protein diphtheria toxoid (dPNAG-DT)
to induce high titers of opsonic and protective antibodies [4]. In
addition to the potential additive/synergistic activity between
antibodies to dPNAG and ClfA the synthesis of a bivalent
dPNAG-CflA vaccine is also aimed to potentially expand the
coverage of a single-component vaccine to include S. aureus strains
expressing only one of the vaccine components.
Specifically this study investigated the value of ClfA as a carrier
protein for dPNAG, the functional activity and specificity of
antibodies to the dPNAG-ClfA vaccine using anti-adhesive and
opsonic killing assays, and protective efficacy in a mouse model of
S. aureus bloodstream infection.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal protocols were reviewed and approved by the Harvard
Medical Area Standing Committee on Animals IACUC which has
Animal Welfare Assurance of Compliance number A3431-01 on
file with the Office of Laboratory Animal Welfare of the U.S.
Public Health Service. During all animal experimentation
procedures all efforts were made to minimize suffering.
Studies involving human subjects were approved by the
Partners Health Care System Institutional Review Board (IRB).
All subjects donating blood provided written informed consent to
participate in the studies.
Bacterial strains and growth conditions
The strains used in this work (Table 1) were routinely grown to
stationary phase in tryptic soy broth (TSB) supplemented with 1%
glucose. When necessary, TSB as well as tryptic soy agar (TSA)
were supplemented with ampicillin (100 mg/ml), tetracycline
(10 mg/ml) or erythromycin (10 mg/ml).
PCR detection of icaABCD and clfA genes in S. aureus
strains
Primers pairs icaF (59-CCAGAGAAATTAGATATTCATT-
GAACAAGAAGC-39)/icaR (59-CATGCCGACACCTATACA-
TAATCCTAAAATGAA-39) and ClfA-F (59-CGGAAAAAATC-
GATTGGCGTGGCTT-39)/ClfA-R (59-GTAATGAACCTAT-
TGATGCTAATAATCCCCA-39) were used to amplify the entire
icaABCD locus or the clfA gene, respectively, from genomic DNA
extracted from the strains S. aureus Newman, 476 and MN8. The
genomic DNA was isolated by using the Wizard genomic DNA
purification kit (Promega) according to the manufacturer’s
instructions.
Purification of clumping factor A
Recombinant clumping factor A (ClfA) protein, residues (221–
559), containing an N-terminal extension of six histidine residues
was expressed from the plasmid pCF41carried by E. coli XL-1 Blue
and kindly provided by Dr Timothy Foster. E. coli was grown in
LB supplemented with ampicillin in a 6-liter fermentor at 37uC
until the optical density at 650 nm (OD650 nm) reached 1. The
temperature was maintained at 37uC, isopropyl b-D-1-thiogalac-
topyranoside (IPTG) was added to a final concentration of
0.5 mM, and growth was continued for 3 h. Cells were pelleted
(6,000 g610 min at 4uC), resuspended in 30 ml of phosphate-
buffered saline (PBS) with complete EDTA-free protease inhibitor
cocktail (Roche Applied Science) and sonicated using 3 cycles of
20 s at 4 W (Sonic Dismembrator) followed by 10 s of rest in an
ice-water bath. After cell debris was removed by centrifugation
(6,000 g610 min at 4uC), the supernatant was filtered and ClfA
purified by affinity chromatography on a Ni2-chelate column
(Novagen) following the manufacture’s instructions. The protein
was further purified by size exclusion chromatography (SEC) on
Sephacryl S-200 (Amersham Biosciences) and endotoxin removed
using Detoxi-Gel (Pierce, Rockford, IL).
Coupling of dPNAG to ClfA
ClfA was coupled to purified dPNAG using the reductive
amination reaction. Aldehyde groups were introduced onto the
surface of ClfA by treating the protein with an excess of
glutaraldehyde and the activated ClfA was subsequently reacted
with dPNAG using the abundant free amino groups present on
this polysaccharide in the presence of sodium cyanoborohydride
(NaBH3CN) (Matreya, Pleasant Gap, PA).
Activation of ClfA with glutaraldehyde. ClfA was dissolved
in 0.1 M carbonate buffer pH 10 at a concentration of 10 mg/ml
and glutaraldehyde (Sigma) added to a final concentration of
1.25% v/v. This reaction was allowed to proceed for 2 h at room
temperature and the gluraldehyde-activated protein dialyzed
against PBS pH 7.4.
Coupling of glutaraldehyde-activated ClfA to
dPNAG. dPNAG was first dissolved in 5M HCl, neutralized
with an equal volume of 5 M NaOH and diluted in PBS pH 7.5 to
a final concentration of approximately 5 mg/ml. This dPNAG
solution was then mixed with an equal amount of gluraldehyde-
activated ClfA in PBS and the pH adjusted to 7.5. Purified
NaBH3CN was added to the mixture in a 20-fold excess over the
amount of each of the components and the reaction allowed to
proceed in the dark for 14 h at 37uC with mixing. After the
conjugation reaction was completed the high molecular weight
(MW) conjugate was purified from uncoupled dPNAG and ClfA
by gel filtration chromatography on a Superose 6-prep-grade
column (Amersham Biosciences). Fractions containing dPNAG-
ClfA conjugate vaccine, which were identified on the basis of the
earlier elution of both polysaccharide and protein compared with
the elution of the non-conjugated components, were pooled,
dialyzed against 20 mM HEPES buffer plus 50 mmM NaCl pH 8
and stored frozen at 220uC.
Chemical analysis of dPNAG-ClfA conjugate vaccine
The dPNAG-ClfA conjugate vaccine was analyzed for its
content of polysaccharide using hexosamine assay described by
Smith and Gilkerson [5] with N-acetylglucosamine as the standard
Bivalent Vaccine for S. aureus Infections
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albumin (BSA) as the standard.
Antiserum production
Antisera to purified dPNAG-ClfA were raised in various animal
hosts including two rabbits, two rhesus monkeys and a goat.
Antibodies to dPNAG-ClfA were raised in New Zealand White
rabbits by subcutaneous (SC) immunization with two 10 mg doses
of conjugated polysaccharide emulsified for the first dose in
complete Freund’s adjuvant and for the second dose in incomplete
Freund’s adjuvant, followed 1 week later by three intravenous (IV)
injections of antigen in saline spaced 3 days apart. Rabbits were
bled every 2 weeks and sera tested by the enzyme-linked
immunosorbent assay (ELISA). Immune sera to dPNAG-ClfA
was also raised in two rhesus monkeys by SC vaccination with a
single dose of 100 mg of dPNAG-ClfA vaccine in aluminum
hydroxide gel adjuvant (Alhydrogel 1.3%, Brenntag Biosector).
Finally, a goat was immunized with the dPNAG-ClfA conjugate
vaccine following the protocol described earlier for rabbits but
with doses of 50 mg per injection in Freund’s incomplete adjuvant.
Serum samples used to compare the immunogenicity of the
dPNAG-ClfA vaccine in rabbits, monkeys and a goat were
collected four weeks after the last immunization.
Immunogenicity of dPNAG-ClfA vaccine in mice
Groups of 10 mice (Swiss-Webster; female, 5–7 weeks of age)
were immunized SC 3 times, 1 week apart, with 1, 5 or 10 mgo f
conjugated polysaccharide suspended in PBS. Blood was with-
drawn weekly for a month and antibody titers to both dPNAG and
ClfA determined by ELISA. Control groups received a mixture of
unconjugated polysaccharide and protein in PBS in the same ratio
as in the conjugate vaccine.
ELISA
dPNAG and ClfA-specific antibodies were measured in sera
obtained from mice, rabbits, monkeys and a goat by ELISA as
described previously [7]. Purified dPNAG and ClfA were used to
sensitize the ELISA plates at a concentration of 0.3 or 10 mg/ml
respectively in phosphate buffer, pH 7.4.
Phagocyte-dependent killing assays
Polymorphonuclear cells (PMNs) were prepared from fresh
human blood collected from healthy adult volunteers as described
earlier [4] under a protocol approved by the Institutional Review
Board of Partner’s Healthcare System and the concentration
adjusted to 2.5610
7/ml in modified minimal essential medium
(MEM)+1% BSA.
The complement source (1 ml of rabbit serum, Sigma) was
adsorbed three times with S. aureus Newman at 4uC for 30 min in
order to remove all non-specific antibodies present. After
adsorption, the complement solution was centrifuged and filter
sterilized.
The test sera for the OPK, goat antibodies to dPNAG-ClfA
conjugate vaccine and normal goat sera (NGS), were first heated at
56uC for 30 min to inactivate endogenous complement activity
and then absorbed three times at 4uC for 30 min with the PNAG-
negative strain Newman Dica or the DclfA mutant DU5852 to
remove antibodies not directed to the PNAG or ClfA antigens,
respectively. The bacteria were then removed by centrifugation
and the test sera filter sterilized.
Overnight cultures of the bacterial strains to be evaluated in
OPKA were diluted 1:100 in fresh TSB+1% glucose, grown to an
OD650 nm of 0.4 (,3610
8 colony forming units (CFU)/ml), and
the final concentration adjusted to 4610
6 CFU/ml in MEM-1%
BSA for use in the killing assay.
The actual phagocytic killing assay was performed by mixing
100 ml (each) of the PMNs suspension, target bacteria, dilutions of
test sera, and the complement source. The reaction mixture was
incubated on a rotor rack at 37uC for 90 min; samples were taken
at time zero and after 90 min. A 10-fold dilution was made in TSB
with 0.05% Tween to prevent bacterial aggregation, and samples
were plated onto TSA plates. Tubes lacking any serum and tubes
with NGS were used as controls, as were tubes containing serum
and complement but lacking PMNs to control for potential
aggregation of bacteria by the antibody, which would reduce the
apparent CFU counts at the end of the assay. At the concentra-
tions of antisera used in the opsonic killing assay, there was no
reduction in CFU of .10% in samples lacking phagocytes but
containing antibody and complement, indicating little agglutinat-
ing activity of the antibodies raised to dPNAG-ClfA vaccine. The
percentage of killing was calculated by determining the ratio of the
number of CFU surviving in the tubes with bacteria, leukocytes,
complement, and goat anti-dPNAG-ClfA sera to the number of
CFU surviving in tubes with the same components but containing
NGA.
For inhibition studies, goat antiserum raised to dPNAG-ClfA
was diluted 1:10 and incubated for 90 min at 4uC with an equal
volume of a solution containing 25 to 200 mg/ml of either purified
dPNAG or ClfA. Subsequently, the antiserum was centrifuged,
Table 1. Bacterial strains used in this study.
S. aureus strains Description Source
Newman Serotype 5 strain [19]
Newman Dica Newman Dica::tet; Tet
R [20]
DU5852 Newman clfA::Tn917; Ery
R [21]
MN8 Serotype 8 strain [22]
476 Non-typable strain [23]
E. coli strains
E. coli XL1-Blue pCF41-(221–559) Derivative of expression plasmid pQE30 (Qiagen Inc.) containing
codons for ClfA amino acids 221–559. Used for the purification of
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described above.
Murine bacteremia model
Groups of eight mice (FVB; female; 3–5 weeks of age) were
immunized intraperitoneally (IP) with 0.4 ml of heat-inactivated
(56uC for 30 min) immune goat sera raised to dPNAG-ClfA,
dPNAG-DT (dPNAG conjugated to diphtheria toxoid protein)
vaccines, or NGS 48 and 24 h before infection. Mice were
challenged IV with the S. aureus strains Newman (4.3610
7 CFUs),
MN8 (8.6610
6 CFUs), 476 (6.7610
5 CFUs), Newman Dica
(7.5610
7 CFUs) or DU5852 (3.5610
7 CFUs), at the doses
indicated, in 0.2 ml of PBS. Two hours later mice were sacrificed
and samples of 0.5 ml blood obtained from the heart, mixed with
20 ml of heparin (Sigma), and plated onto TSA plates. Bacteremia
was quantified by colony counts after overnight growth and values
expressed as CFU/ml of blood.
Preparation of affinity purified antibodies to ClfA
Three grams of CNBr-activated Sepharose 4B gel (Pharmacia
Biotech, Uppsala, Sweden) was suspended in 250 ml of 1 mM
HCl for 30 min at 4uC, and then the gel was washed with
alternating amounts of 750 ml of 1 mM HCl, 100 ml of distilled
water, and 300 ml of reaction buffer containing 0.1 M NaHCO3
and 0.5 M NaCl (pH 8.3). The gel was suspended in 10 ml of the
reaction buffer (pH 8.3), incubated with 5 mg of ClfA overnight at
4uC, and then the coupled gel was packed into a low-pressure
column and washed with 250 ml of 1 M glycine in reaction buffer
(pH 8.3) to block unused activation sites. Subsequently, the
coupled gel was washed three times with alternating 200 ml
amounts of borate buffer containing 0.1 M boric acid and 1 M
NaCl (pH 8.5), 100 ml of distilled water, 200 ml of acetate buffer
containing 0.1 M sodium acetate and 1 M NaCl (pH 4.0), and
100 ml of distilled water and then was suspended in PBS.
Ten ml of rabbit antiserum raised to dPNAG-ClfA was passed
through a CNBr-activated Sepharose 4B-packed affinity column
that was immobilized with ClfA. After intensive washing with PBS,
the specific anti-ClfA immunoglobulins, which bound to the beads
were eluted with 0.1 M glycine-HCI, pH 2.7 buffer and collected
into fractions that were immediately neutralized with 1 M Tris
base buffer ammonium bicarbonate, pH 9 and monitored for their
absorbance at OD280 nm. Fractions containing affinity-purified
rabbit antibodies specific to ClfA were then pooled and quantified
for protein content with the Bradford assay [6] using rabbit IgG as
standart.
Adherence of S. aureus to immobilized fibrinogen
Adherence of S. aureus to fibrinogen (Fn) (Sigma) was assessed in
96-well polystyrene plates coated for with 400 ng/well of Fn for
1 h at 37uC after which the remaining sites were blocked by with
200 ml of PBS 1% BSA for 1 h at 37uC.
The S. aureus strains Newman, MN8, 476 and the Newman
DclfA derivative DU5852 were grown overnight on TSA plates,
harvested by centrifugation, washed with PBS pH 7.2 and
resuspended in PBS to an OD650 nm of 1.0. S. aureus cultures
were then further concentrated 5 fold and pre-incubated with
either rabbit affinity-purified antibodies to ClfA or control non-
immune polyclonal rabbit IgG at concentrations ranging from
0.8–500 mg/ml in PBS for 1 h at room temperature. After Fn-
coated plates were incubated with the S. aureus strains for 1 h at
room temperature, wells were washed three times with PBS and
bound cells fixed with 200 ml of glutaraldehyde (2% v/v in PBS)
for 1 h and stained with crystal violet (Sigma) (0.5% v/v) for
5 minutes. Plates were rinsed with water, air-dried and the
absorbance at 595 nm (OD595 nm) determined using an ELISA
plate reader (BioTek Instruments, Winoski, Ill).
Confocal laser scanning microscopy
Confocallaserscanningmicroscopy(CLSM)wasused toevaluate
the production of PNAG and ClfA in three S. aureus strains,
Newman, MN8 and 476. S. aureus strains were grown overnight at
37uC in TSB supplemented with 1% glucose, washed twice with
PBS and blocked overnight with PBS 1% BSA and 10% normal
rabbit sera (NRS). Cells were washed twice with PBS and a 10 ml
aliquot of the cell suspension was air-dried onto a glass slide.
Bacteria were fixed to the slide with methanol for 1 min at room
temperature. At this point S. aureus samples were incubated for 2 h
at room temperature with antibodies to PNAG (human monoclonal
antibody(mAb) F598conjugatedtoAlexaFluor488)andClfA (goat
dPNAG-CflA sera that had been previously absorbed four times at
4uC with the ClfA-negative S. aureus strain DU5852) in PBS with
0.5% BSA and 10% NRS. As controls we included S. aureus samples
labeled with a human alginate-specific mAb F429 conjugated to
Alexa Fluor 488 and NGS that had been previously absorbed with
S. aureus DU5852. Samples were washed three times with PBS and
further incubated for 1 h at room temperature with a secondary
donkey anti-goat IgG conjugated to Alexa Fluor 568 (Invitrogen)
diluted 1:250 in PBS 0.5% BSA plus the nucleic acid stain Syto 62,
(Invitrogen) at a final concentration of 5 mM. Samples were washed
twice with PBS, and mounted with Mowiol mounting media and a
glass coverslip and observed with a Zeiss LSM 5 Pascal confocal
inverted microscope equipped with an Argon 488 nm laser, a
HeNe1 543 nm laser, and a HeNe2 633 nm laser. Samples were
viewed with a Plan Apochromat 636/1.4 oil objective and data
analyzed with Zeiss LSM Imaging software.
Statistical analysis
All statistical analyses were performed with Prism 4.0 (GraphPad
Software, http://www.graphpad.com/). An unpaired t test was
used to compare the IgG antibody titers generated against ClfA
between mice immunized with the conjugate dPNAG-ClfA vaccine
and the mixture of unconjugated dPNAG+ClfA. One-way analysis
of variance (ANOVA) was applied for comparisons of the
opsonophagocytic killing among the isogenic S. aureus Newman
strains and the protective efficacy of dPNAG-DT and dPNAG-ClfA
antibodies versus NGS in bacteremia studies followed by Tukey’s
post-hoc test. A P-value of ,0.05 was considered significant.
Results
Synthesis of dPNAG-ClfA conjugate vaccine
ClfA and dPNAG were covalently linked via reductive
amination in the presence of NaBH3CN. Results presented in
Figure 1 show that both ClfA (OD595 nm) and dPNAG
(OD650 nm) co-eluted in the void volume of the column (void
volume: approximately 40 ml) and significantly earlier than the
unconjugated dPNAG and ClfA that eluted at approximately 100
and 110 ml, respectively, denoting the formation of a large MW
dPNAG-ClfA conjugate. To identify fractions containing dPNAG-
ClfA conjugate free of unconjugated ClfA and/or dPNAG all
fractions were analyzed by sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis (SDS-PAGE) followed by silver staining.
Fractions in the elution volume of 42–70 ml contained high MW
dPNAG-ClfA conjugate which did not enter the SDS-PAGE gel
(no signal detected by silver staining) whereas the remaining
fractions contained various levels of free dPNAG and/or ClfA and
were not included in the final conjugate vaccine pool (data not
shown).
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were dialyzed overnight against HEPES buffer pH 8 and analyzed
for polysaccharide and protein content using the Gilkerson-Smith
and Bradford assays, respectively. The dPNAG-ClfA conjugate
vaccine contained 31% dPNAG and 69% ClfA.
Immunogenicity of dPNAG-ClfA conjugate vaccine in
various animal species
Mice (n=10) were immunized three times with 1, 5 or 10 mgo f
either the dPNAG-ClfA conjugate or a mix of comparable
amounts of unconjugated dPNAG plus ClfA (dPNAG+ClfA) as a
control. As seen in Fig. 2A mice vaccinated with the dPNAG-ClfA
conjugate responded with IgG antibodies to dPNAG in a dose-
dependent manner. No antibodies to dPNAG were detected in the
mice receiving the unconjugated dPNAG and ClfA mixture (Titer
below level of detection of 25) (Fig. 2A). Similarly, mice vaccinated
with the dPNAG-ClfA conjugate developed dose-dependent
antibody titers to ClfA while the animals given the dPNAG+ClfA
mix responded with significantly lower antibodies to ClfA
(Antibody titers to ClfA in dPNAG-ClfA conjugate versus
dPNAG+ClfA mixture ***P,0.0001 unpaired t test in all three
doses and time points post-immunization except for mice
Figure 1. Size exclusion chromatography profile of dPNAG conjugated to ClfA through a Superose 6 gel column. Fractions were
assayed for polysaccharide by the hexosamine assay (OD650 nm) and for protein with the Bradford assay (OD595 nm). Double-headed arrows indicate
the fractions containing conjugated dPNAG and ClfA, as well as where the unconjugated polysaccharide (dPNAG) and protein (ClfA) eluted.
doi:10.1371/journal.pone.0043813.g001
Figure 2. Immunogenicity of dPNAG-ClfA vaccine in mice. Mean titers of IgG antibodies to PNAG and ClfA in sera from mice (n=10)
immunized three times at weekly intervals with 1, 5 or 10 mg of dPNAG2ClfA conjugate vaccine or dPNAG mixed with ClfA (dPNAG+ClfA). Sera were
collected weekly for 4 weeks starting 1 week after the last immunization and were tested by ELISA for antibodies to dPNAG and ClfA. A) IgG antibody
levels to dPNAG in sera of mice vaccinated with dPNAG2ClfA conjugate vaccine or a mixture of unconjugated dPNAG+ClfA. Horizontal line depicts
the limit of detection (titer=25). For clarity, titers from mice receiving the mixture dPNAG+ClfA, which were below the limit of detection, were
assigned a value of the limit of detection. B) IgG antibody titers to ClfA in sera of mice given the dPNAG2ClfA conjugate vaccine or control
dPNAG+ClfA. Bars represent means and error bars indicate standard deviations. P as determined by unpaired t test. * P,0.05, ** P,0.005 and ***
P,0.0001. All pre-immune titers were ,25.
doi:10.1371/journal.pone.0043813.g002
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were *P,0.05 and **P,0.005, respectively) (Fig. 2B).
The immunogenicity of dPNAG-ClfA was also evaluated in two
rabbits, two rhesus monkeys and a goat. As shown in Table 2 the
dPNAG-ClfA vaccine was highly immunogenic in all three of
these animal species, eliciting high antibody titers to both dPNAG
and ClfA antigens. Interestingly there were differences in the levels
and the relative response to each vaccine component among the
three animal hosts. These differences might be explained in terms
of doses, immunization regimes and/or host-specific differences
among the various animal hosts.
Characterization of PNAG and ClfA production in S.
aureus Newman, MN8 and 476 strains
PCR amplification of the icaABCD locus and cflA genes from
genomic DNA extracted from three representative S. aureus strains
Newman (CP5), MN8 (CP8) and 476 (non-typable) resulted in
amplification bands with sizes consistent of those of the icaABCD
(3,415 bp) and clfA (2,802 bp) genes of S. aureus (data not shown).
In addition to PCR we conducted confocal laser scanning
microscopy (CLSM) studies to investigate the production of PNAG
and ClfA by these three S. aureus strains. For these experiments
PNAG was labeled with the human IgG1 mAb F598 specific to
PNAG directly conjugated to Alexa fluor 488 (F598-AF488) and
ClfA was labeled with goat antibodies raised to the dPNAG-ClfA
antibodies that had been previously absorbed with S. aureus
Newman DU5852 (DclfA) to remove all antibodies raised to
dPNAG followed by a secondary donkey anti-goat IgG AF568. As
controls, bacterial samples were stained with a human IgG1 mAb
to Pseudomonas aeruginosa alginate, mAb F429, also directly
conjugated to AF488 and with non-immune goat serum. As
presented in Figure 3A (first and second columns) there were high
levels of ClfA (red channel) and PNAG (green channel) antigens
detected by specific antibody binding in all three S. aureus strains.
Conversely, S. aureus staining with control mAb F429-AF488 and
NGS resulted in almost undetectable levels of red or green
fluorescent labels, (Fig. 3B first and second columns, respectively).
Labeling with the nucleic acid-specific Syto 62 fluorescent dye was
also included in the experiments and results shown in the third
columns of both panels.
Inhibition of S. aureus binding to fibrinogen by
antibodies to ClfA
Affinity purified antibodies specific to ClfA or control rabbit
IgG were incubated at concentrations ranging from 0.8 to 500 mg/
ml with S. aureus bacteria which were then added to Fn-coated
microtiter plates. Bacterial binding was detected by crystal violet
staining and quantification at OD595 nm. As shown in Figure 4
affinity-purified antibodies to ClfA were highly effective at
blocking the binding of the three S. aureus strains Newman,
MN8 and 476 to immobilized Fn in a dose-dependent manner. In
addition, there was no detectable binding of the ClfA-negative
strain S. aureus DU5852 to immobilized Fn (data not shown).
Phagocyte-dependent killing by goat antibodies to the
dPNAG-ClfA conjugate vaccine
As shown in Figure 5A, antisera to dPNAG-ClfA at a 1:10
dilution promoted the killing of wild type S. aureus Newman (54%
killing) but there was no killing of the PNAG-negative strain
Newman Dica (5.4% killing) (Killing of S. aureus Newman versus
Dica; P,0.001, one-way ANOVA). This antiserum also killed the
ClfA-negative mutant DU5852 but to a lower extent (35% killing)
(Killing of S. aureus Newman versus DU5852; P,0.01, one-way
ANOVA). This reduction in susceptibility of the ClfA-negative
Table 2. IgG titers to dPNAG and ClfA in various animal host species including two rabbits, two rhesus monkeys and a goat
vaccinated with dPNAG2ClfA.
Coating Antigen Rabbit 1 Rabbit 2 Monkey 1 Monkey 2 Goat
dPNAG 1,330,000 1,220,000 10,858 26,389 506,433
ClfA 102,000 107,000 730 719 1,118,184
Serum samples from all animal hosts, collected four weeks after the last immunization, were measured by ELISA for antibody titers specific to dPNAG and ClfA. Titers
determined by end-point linear regression.
doi:10.1371/journal.pone.0043813.t002
Figure 3. CLSM imaging of ClfA and PNAG expression by S. aureus Newman, MN8 or 476 strains. A) S. aureus labeled with mAb F598 to
PNAG directly conjugated to Alexa Fluor 488 (F598-AF488), goat antibody to dPNAG2ClfA conjugate vaccine that had been previously absorbed with
S. aureus Newman DU 5852 to remove antibody to dPNAG and a secondary donkey antibody to goat IgG conjugated to AF568 and the nucleic acid-
specific fluorescent dye Syto 62. B) S. aureus stained with mAb F429 to P. aeruginosa alginate directly conjugated to AF488, NGS and a secondary
donkey antibody to goat IgG conjugated to AF568 and Syto 62. For both panels A and B, the first, second and third columns represent S. aureus
samples viewed in the red (ClfA), green (PNAG) and blue (bacterial DNA) channels, respectively. Bar=10 mm.
doi:10.1371/journal.pone.0043813.g003
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most likely attributable to the variation in PNAG retention on the
bacterial cell surface when other factors are changed, as retention
is often due to post-synthetic effects such as that of the extracellular
IcaB deacetylase [8,9]. Based on our previous experience in testing
mAbs and polyclonal sera to dPNAG in the OPKA we found that
opsonic killing levels .30% identify antisera with in vivo protective
activity [4,10].
To ascertain the specificity of the OPKA, purified dPNAG or
ClfA were added to diluted antisera then tested for killing activity.
Purified dPNAG inhibited the OPKA of goat antisera to dPNAG-
ClfA conjugate, with inhibition titering out in a dose-dependent
manner (Fig. 5B). ClfA failed to inhibit the opsonic killing of S.
aureus Newman by antibodies elicited by the dPNAG-ClfA
conjugate at all concentrations tested, indicating that the OPKA
measured here was all due to antibody to PNAG.
Protective efficacy of goat antiserum to the dPNAG-ClfA
conjugate vaccine in a murine bacteremia model
We evaluated the ability of goat antisera to the dPNAG-ClfA
conjugate vaccine along with goat antisera raised to a conjugate of
dPNAG and diphtheria toxoid (dPNAG-DT) that had comparable
antibody titers to PNAG, to reduce bacterial levels in the blood of
mice 2 h after IV injection. As shown in Figure 6, mice injected
with antibodies to the dPNAG-ClfA conjugate vaccine had a
significant reduction in blood CFU levels of S. aureus Newman 2 h
post infection in comparison to animals given control NGS. A
comparable reduction in the blood levels of S. aureus Newman was
achieved with the antiserum to the dPNAG-DT conjugate vaccine,
suggesting there was an immeasurable contribution of the
antibodies to ClfA to the protective efficacy of the antibodies to
the dPNAG-ClfA vaccine. Comparable results were also seen with
the S. aureus strains MN8 and 476 (Fig. 6).
When similar protection studies were carried out with S. aureus
DU5852 which does not elaborate ClfA, mice immunized with
dPNAG-DT or dPNAG-ClfA had significantly and comparable
lower bacterial blood levels than animals given non-immune NGS
(dPNAG-DT and dPNAG-ClfA vs NGS P,0.01). On the other
hand mice that had been passively immunized with antisera raised
to the dPNAG-DT vaccine then infected with the PNAG-deficient
strain Newman Dica had no significant changes in blood CFU levels
in comparison to the control NGS (dPNAG-DT vs NGS; ns).
However, mice infected with the Dica strain after passive
immunization with antibodies raised to the dPNAG-ClfA vaccine
exhibited significant bacterial blood clearance in comparison to the
NGS-immunized group (dPNAG-ClfA vs NGS, P,0.01). These
findings indicate that in the presence of the PNAG antigen,
antibodies to ClfA are not effective at mediating protection from
bacteremia. However in the absence of PNAG, the ClfA antigen
could be either significantly more expressed or exposed on the
surface of bacteria, allowing the antibody to ClfA to be protective in
thebacteremia modelofinfection.Presumablythisisbyanon-OPK
mechanism as antibody to ClfA does not appear to have significant
opsonic activity against wild type or Dica S. aureus strains.
Discussion
In this work we report the synthesis of a conjugate vaccine
covalently linking two S. aureus surface components, ClfA and the
Figure 4. Antibody to ClfA inhibits S. aureus binding to immobilized fibrinogen. Affinity-purified rabbit anti-ClfA IgG’s (%) and control non-
immune rabbit IgG’s (&) were tested at various concentrations (0.8 to 500 mg/ml) for the their ability to inhibit the binding of S. aureus Newman,
MN8 or 476 strains to fibrinogen. Fibrinogen-coated plates were incubated with S. aureus for 1 h, fixed with glutaraldehyde for 1 h and stained with
crystal violet (0.5% v/v) for 5 minutes. After plates were air-dried the absorbance at 595 nm (OD595 nm) was determined using an ELISA plate reader.
Data points represent the average of three independent experiments 6 SEM.
doi:10.1371/journal.pone.0043813.g004
Figure 5. Opsonophagocytic killing activity and specificity of
goat sera raised to dPNAG2ClfA conjugate vaccine. A) Opsonic
killing of S. aureus Newman, Dica and DU 5852 (DclfA), by a 1:10 dilution
of goat antiserum raised to dPNAG2C l f Ai nt h ep r e s e n c eo f
polymorphonuclear cells and complement. Bars represent mean
percentages of killing 6 SEM. P as determined by one-way ANOVA
with Tukey’s post-hoc analysis. B) Inhibitory capacity of dPNAG and ClfA
antigens in the opsonophagocytic assay. Inhibition of opsonic killing of
S. aureus Newman by the goat serum raised to dPNAG2ClfA conjugate
vaccine with purified dPNAG (solid bars) or ClfA (open bars) antigens at
the indicated concentration. Bars represent means of three indepen-
dent experiments 6 SEM.
doi:10.1371/journal.pone.0043813.g005
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of mice with this conjugate vaccine dramatically enhanced the
immunogenicity of both components of the vaccine.
The increased immunogenicity of ClfA in dPNAG-ClfA-
vaccinated mice in comparison to animals receiving dPNAG plus
ClfA may be explained in part by the likely enhenced immuno-
genicity of the high molecular weight, highly cross-linked, three-
dimensional structure of the dPNAG-ClfA conjugate in compar-
ison to the mixture of unconjugated ClfA and dPNAG.
On the other hand, the lack of immunogenicity of unconjugated
dPNAG in mice immunized with 1, 5 or 10 mg doses of a mixture
of dPNAG-ClfA was not entirely surprising. Previous studies
carried out in our laboratory have demonstrated that mice
immunized with 100 mg doses of the fully acetylated PNAG, which
was used to prepare the dPNAG for the present study, failed to
elicit a detectable IgG response [7].
The dPNAG-ClfA vaccine was also highly immunogenic in
multiple animal species including rabbits, rhesus monkeys and a
goat wherein vaccination elicited high antibody titers to both
dPNAG and ClfA. Although the total number of animals
immunized was limited to two rabbits, two monkeys and a goat
we found relative differences in antibody responses to dPNAG and
ClfA among the different animal hosts. These could relate to
differences in vaccine dosage (10, 50 and 100 mg doses for rabbits,
goat and monkeys respectively), immunization protocol (2 SC
injections followed by 3 IV doses in rabbits and goat versus one
single SC dose for the monkeys), type of adjuvant (Freund’s
incomplete for rabbits and the goat or alum for monkeys), used
and/or to host-specific responses.
The goat antiserum was found to mediate opsonic killing of S.
aureus that was specific to the dPNAG antigen. In addition, we
found that affinity-purified antibodies to ClfA inhibited the
adherence of three S. aureus strains to immobilized Fn in vitro.
However, antibody to ClfA had negligible opsonic activity against
S. aureus Newman and did not augment the protective efficacy of
Figure 6. Protective efficacy of dPNAG2ClfA vaccine in a murine bloodstream infection model. Comparative protective efficacy elicited
by goat immune sera raised to dPNAG2ClfA and dPNAG-DT conjugate versus NGS against S. aureus strains Newman, MN8, 476, Newman Dica,o r
DU5852 in a murine bacteremia model. Groups of eight FVB mice were immunized IP with 0.4 ml of heat-inactivated antisera raised to dPNAG-DT,
dPNAG2ClfA vaccines or with control NGS, 48 and 24 h before IV challenge with the S. aureus strains Newman (4.3610
7 CFUs), MN8 (8.6610
6 CFUs),
476 (6.7610
5 CFUs), Newman Dica (7.5610
7 CFUs), or DU5852 (3.5610
7 CFUs), sacrificed 2 h post infection and the number of CFU/ml of blood
estimated by serial dilutions and plating. Bars indicate the mean CFU per ml of blood, error bars the SEM. P values as determined by one-way ANOVA
with Tukey’s post-hoc analysis. (ns: not significant).
doi:10.1371/journal.pone.0043813.g006
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three PNAG- and ClfA-positive strains of S. aureus
Previous reports have demonstrated that the use of single
vaccine antigens such as CP or ClfA resulted in protection of
animals against S. aureus infections [11–14] but single component
vaccines have failed in all human trials to date [3]. We therefore
reasoned that the combination of PNAG and ClfA in the form of a
bivalent dPNAG-ClfA conjugate vaccine might be required to
confer full protection against S. aureus infection and/or to broaden
the vaccine coverage to include S. aureus strains which do not
fabricate either PNAG or ClfA. Moreover since S. aureus capsular
polysaccharide have been shown to mask clumping factor A-
mediated adherence of S. aureus to fibrinogen and platelets [15]
then the addition of PNAG to ClfA-based vaccines might be
advantageous.
The evidence presented in this work is in full agreement with
previous reports showing that either polyclonal or monoclonal
antibodies against ClfA inhibit the binding of S. aureus to
immobilized fibrinogen in vitro [11,16,17], thought to be one
correlate of protective efficacy. However, the sera raised to the
dPNAG-ClfA conjugate was no better than antibodies raised to
dPNAG conjugated to DT at reducing blood levels of S. aureus
following IV challenge with three strains. These findings are
consistent with a previous report showing that passive immuniza-
tion of mice with affinity-purified ClfA specific antibodies could
not prolong the survival in a sepsis model after receiving an
intravenous lethal challenge of S. aureus N315 or S. aureus MW2
[18].
In conclusion the conjugation of dPNAG to ClfA, enhanced the
immunogenicity of each component of the vaccine and elicited
functional anti-adhesive and opsonic/protective antibodies specific
to ClfA and dPNAG, respectively. However the lack of opsonic
activity of antibodies to ClfA against wild type S. aureus Newman
combined with their negligible protective efficacy against wild type
S. aureus strains expressing PNAG suggests no major role for
immunity to ClfA in S. aureus bacteremia. While levels of the
PNAG-defective mutant of S. aureus Newman were reduced in the
blood of mice passively administered the antibody to dPNAG-
ClfA, this situation is not representative of human infections which
occur almost exclusively with PNAG-producing S. aureus. Antibody
to ClfA might be useful in other settings of S. aureus infections but
incorporation of this bacterial component into a vaccine is made
difficult by the poor availability of the antigen to antibodies when
surface capsules, including both CP5 or CP8 and PNAG are made
[15]. Coupled with the failure of the clinical trial using ClfA-
enriched human immune globulins for prevention of S. aureus
infections in neonates it appears that validating use of either
passive antibody to this antigen or inclusion of ClfA in a vaccine
will require better definition of where, when and how immunity to
ClfA could augment human resistance to S. aureus infection.
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